Last Price
4.37
Today's Change
+0.01 (0.22%)
Day's Change
4.32 - 4.46
Trading Volume
31,886
Market Cap
186 Million
Shares Outstanding
42 Million
Avg Volume
52,129
Avg Price (50 Days)
3.90
Avg Price (200 Days)
3.13
PE Ratio
-8.57
EPS
-0.51
Earnings Announcement
11-Nov-2024
Previous Close
4.36
Open
4.46
Day's Range
4.32 - 4.46
Year Range
1.9382 - 4.95
Trading Volume
31,886
1 Day Change
0.23%
5 Day Change
4.55%
1 Month Change
8.44%
3 Month Change
50.69%
6 Month Change
46.64%
Ytd Change
54.42%
1 Year Change
95.09%
3 Year Change
8.44%
5 Year Change
113.17%
10 Year Change
-44.89%
Max Change
-83.18%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.